Skip to main content

Cancer Early Detection REACH

Status: Open to Enrollment
Email us to enroll

Study details

View study details on clinicaltrials.gov.

Locations

  • Sacramento
  • Palo Alto
  • Roseville
  • Davis
  • Elk Grove
  • Santa Rosa
  • Fairfield
  • Auburn
  • Modesto
  • Sunnyvale
  • Santa Cruz

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test. The study will seek to enroll approximately 20% of the study participants from under-represented minority populations (e.g., racial / ethnic minority groups, socioeconomically disadvantaged populations, rural populations).

Charles H McDonnell, III, M.D., FACR
Charles H McDonnell, III, M.D., FACR
Principal investigator
View profile
Natalia Colocci, M.D., Ph.D.
Natalia Colocci, M.D., Ph.D.
Principal investigator
View profile

Related clinical trials

View all clinical trials
  • Clinical trial

    Advanced Staged Cancer Targeted Therapy ASCO TAPUR

    Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Status: Open to Enrollment

  • Clinical trial

    Adverse Effects of Chemotherapy Shengbai Solution

    A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB

    FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Advanced Pancreatic Adenocarcinoma

    Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Astrocytomas Grade 3 A072301

    Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?